⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055414 | 1.00 | — | — | |
| SCHEMBL22920101 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL28310281 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3600107 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6870898 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29288193 | 0.97 | — | — | |
| SCHEMBL221055 | 0.87 | — | — | |
| SCHEMBL572346 | 0.87 | — | — | |
| SCHEMBL240170 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL25236164 | 0.85 | GLI1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | claimed |
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | claimed |
| CN-114728950-B | Compounds useful as inhibitors of HELIOS proteins | 百时美施贵宝公司 | 2024-10-18 | — | — | CN | claimed |
| CN-114746414-B | Aza-quinoline compounds and uses thereof | 诺华公司 | 2024-10-18 | — | — | CN | claimed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | claimed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | claimed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | claimed |
| CN-111601798-B | Bisamide sarcomere activating compounds and uses thereof | 美国安进公司 | 2023-08-11 | — | — | CN | claimed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | claimed |
| EP-4034535-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2022-08-03 | — | — | EP | claimed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | claimed |
| CN-110114349-A | Thiophene derivant as antivirotic | 埃尼奥制药公司 | 2019-08-09 | — | — | CN | claimed |
| CN-104245671-B | nitrogen-containing heterocyclic compound or salt thereof | 富士胶片株式会社 | 2017-03-22 | — | — | CN | claimed |
| CN-103237801-B | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS Co.,Ltd. (KR) | 2015-11-25 | — | — | CN | claimed |
| CN-102762576-B | Benzoxazepine PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2015-04-22 | — | — | CN | claimed |
| CN-103237801-A | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS CO LTD | 2013-08-07 | — | — | CN | claimed |
| EP-2464368-A1 | CATHEPSIN C INHIBITORS | Glaxo Group Limited (GB) | 2012-06-20 | — | — | EP | claimed |
| CN-122029167-A | Condensed heteroaryl compound, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260085034-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2026-03-26 | — | — | US | disclosed |
| US-20260083722-A1 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SCRIPPS RESEARCH INST (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260042771-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4172157-B1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | disclosed |
| US-12351579-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4570795-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | Astellas Pharma, Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025090774-A1 | CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE | SEAGEN INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119604495-A | Heterocyclic compounds for inducing G12V mutant KRAS protein degradation | 安斯泰来制药株式会社 | 2025-03-11 | — | — | CN | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250034167-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-01-30 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4486444-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118871103-A | Imidazopyridine tyrosine kinase inhibitors | 布里奇恩生物科学公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-114746414-B | Aza-quinoline compounds and uses thereof | 诺华公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-114728950-B | Compounds useful as inhibitors of HELIOS proteins | 百时美施贵宝公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-12077537-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118574893-A | Polycarbonate resin composition and molded article | 株式会社钟化 | 2024-08-30 | — | — | CN | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-118290881-A | Masterbatch and method for producing thermoplastic resin composition | 株式会社钟化 | 2024-07-05 | — | — | CN | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-117881397-A | Heterocyclic compounds and methods of use | 安进公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024034593-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| CN-117263839-A | Synthesis method of substituted nitrogen heterocyclic compound | 苏州爱玛特生物科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| WO-2023225625-A2 | BIFUNCTIONAL DEGRADERS COMPRISING ELECTROPHILIC PROTACS THAT ENGAGE DCAF1 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230364085-A1 | USE OF MODULATORS OF CCR5 IN THE TREATMENT OF CANCER AND CANCER METASTASIS | PESTELL RICHARD G (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312567-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| CN-111601798-B | Bisamide sarcomere activating compounds and uses thereof | 美国安进公司 | 2023-08-11 | — | — | CN | disclosed |
| WO-2023143401-A1 | COMPOUND SERVING AS MASP-2 INHIBITOR, PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | 武汉朗来科技发展有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-11680064-B2 | Capsid inhibitors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| CN-116209716-A | Processing aid for vinyl chloride resin composition | 株式会社钟化 | 2023-06-02 | — | — | CN | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4172157-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115996925-A | Capsid inhibitors for the treatment of HIV | 吉利德科学公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | disclosed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20230038823-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | AMGEN INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4061812-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | Bristol-Myers Squibb Company (US) | 2022-09-28 | — | — | EP | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-09-08 | — | — | US | disclosed |
| EP-4034535-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-4011870-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022081807-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-110114349-B | Thiophene derivatives as antiviral agents | 埃尼奥制药公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2021262990-A1 | CAPSID INHIBITORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20210371419-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-12-02 | — | — | US | disclosed |
| US-11117896-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-09-14 | — | — | US | disclosed |
| CN-113396145-A | PFKFB3 inhibitors and uses thereof | 盖罗发现有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20200048253-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-13 | — | — | US | disclosed |
| US-10556905-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-02-11 | — | — | US | disclosed |
| CN-106661017-B | Bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2019-09-24 | — | — | CN | disclosed |
| EP-2857401-B1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2019-09-18 | — | — | EP | disclosed |
| CN-110114349-A | Thiophene derivant as antivirotic | 埃尼奥制药公司 | 2019-08-09 | — | — | CN | disclosed |
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| US-20190127366-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2019-05-02 | — | — | US | disclosed |
| CN-109310675-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| CN-108912029-A | Nitrogen-containing heterocycle amide derivatives and application thereof | 广东东阳光药业有限公司 | 2018-11-30 | — | — | CN | disclosed |
| EP-2951170-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| CN-105612153-B | Substituted heterocyclic sulfonamide compound as TRPA1 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-09-14 | — | — | CN | disclosed |
| US-20180258089-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-10023573-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| CN-108024992-A | Aryl, Heteroaryl and Heterocyclic Compounds for the Treatment of Medical Disorders | 艾其林医药公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-107759503-A | A kind of tetracycline derivant and application thereof | 四川科伦博泰生物医药股份有限公司 | 2018-03-06 | — | — | CN | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| CN-107530329-A | Pyrazolo [1,5 a] [1,3,5] triazine and pyrazolo [1,5 a] pyrimidine derivatives as CDK inhibitor | 奥瑞基尼探索技术有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| US-20170233393-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-9708320-B2 | β-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| CN-106661017-A | novel bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2017-05-10 | — | — | CN | disclosed |
| CN-104245671-B | nitrogen-containing heterocyclic compound or salt thereof | 富士胶片株式会社 | 2017-03-22 | — | — | CN | disclosed |
| CN-103702980-B | Cyclic amine derivatives as EP 4 receptor antagonists | 罗达制药生物技术有限责任公司 | 2016-10-05 | — | — | CN | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| CN-105612153-A | Substituted sulfonamide compounds as TRPA1 conditioner | HOFFMANN LA ROCHE | 2016-05-25 | — | — | CN | disclosed |
| US-20160024090-A1 | BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-28 | — | — | US | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| CN-103237801-B | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS Co.,Ltd. (KR) | 2015-11-25 | — | — | CN | disclosed |
| US-9181250-B2 | Beta-lactamase inhibitor and process for preparing the same | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20150141401-A1 | NOVEL BETA-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-05-21 | — | — | US | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| EP-2857401-A1 | NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME | Meiji Seika Pharma Co., Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| CN-103328442-A | Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases | GALAPAGOS NV | 2013-09-25 | — | — | CN | disclosed |
| CN-103237801-A | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS CO LTD | 2013-08-07 | — | — | CN | disclosed |
| EP-2448946-B1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| EP-2464368-A1 | CATHEPSIN C INHIBITORS | Glaxo Group Limited (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| CN-102471339-A | Pyrrolopyridine inhibitors of kinases | ABBOTT LAB | 2012-05-23 | — | — | CN | disclosed |
| EP-2448946-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | Novartis AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2443107-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2443107-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2012-04-25 | — | — | EP | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| US-7960582-B2 | Process for the preparation and resolution of mandelic acid derivatives | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| WO-2011000855-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
| US-20100298286-A1 | Organic Compounds | NOVARTIS AG | 2010-11-25 | — | — | US | disclosed |
| WO-2010120854-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-2238134-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| CN-101506199-A | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-12 | — | — | CN | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080705-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20080312457-A1 | Process | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080293965-A1 | Process for the Dynamic Resolution of (Substituted) (R)- or (S)- Mandelic Acid | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| CN-100434420-C | Compounds that block dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO (JP) | 2008-11-19 | — | — | CN | disclosed |
| WO-2008095912-A2 | ENANTIOPURE PHARMACOLOGICALLY ACTIVE TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| CN-101180256-A | Method for kinetic resolution of (substituted) (R) -or (S) -mandelic acids | ASTRAZENECA AB ASTRAZENECA UK (SE) | 2008-05-14 | — | — | CN | disclosed |
| US-7345180-B2 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| EP-1888499-A1 | A PROCESS FOR THE DYNAMIC RESOLUTION OF (SUBSTITUTED) (R) - OR (S) -MANDELIC ACID | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| CN-101107220-A | Amide derivatives as inhibitors of histone deacetylase | ANGELETTI P INST RICHERCHE BIO (IT) | 2008-01-16 | — | — | CN | disclosed |
| CN-100350036-C | Apparatus and method for controlling biofilms | PROCTER & GAMBLE (US) | 2007-11-21 | — | — | CN | disclosed |
| CN-1327766-C | Compounds, compositions, and methods for controlling biofilms | PROCTER & GAMBLE (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-1307875-C | Compounds, compositions and methods for controlling biofilms | PROCTER & GAMBLE (US) | 2007-04-04 | — | — | CN | disclosed |
| WO-2006125964-A1 | A PROCESS FOR THE DYNAMIC RESOLUTION OF (SUBSTITUTED) (R) - OR (S) -MANDELIC ACID | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| US-20060229286-A1 | Compound inhibiting dipeptidyl peptidase IV | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1692089-A2 | A PROCESS FOR RESOLVING, OPTIONALLY SUBSTITUTED, MANDELIC ACIDS BY SALT FORMATION WITH A CHIRAL BASE CYCLIC AMIDE | Astrazeneca UK Limited (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-20060165648-A1 | Compounds, compositions, and methods for controlling biofilms | DEGENHARDT CHARLES R | 2006-07-27 | — | — | US | disclosed |
| US-7018642-B2 | Compounds, compositions, and methods for controlling biofilms | THE PROCTER & GAMBLE COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| CN-1745063-A | Compound inhibiting dipeptidyl peptidase iv | SANWA KAGAKU KENKYUSHO CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| CN-1699545-A | Apparatus and method for controlling biofilms | PROCTER & GAMBLE (US) | 2005-11-23 | — | — | CN | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| CN-1689405-A | Compounds, compositions, and methods for controlling biofilms | PROCTER & GAMBLE (US) | 2005-11-02 | — | — | CN | disclosed |
| WO-2005054168-A2 | A PROCESS FOR RESOLVING, OPTIONALLY SUBSTITUTED, MANDELIC ACIDS BY SALT FORMATION WITH A CHIRAL BASE CYCLIC AMIDE | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | WO | disclosed |
| CN-1527876-A | Compounds, compositions and methods for controlling biofilms | — | 2004-09-08 | — | — | CN | disclosed |
| EP-1381668-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | THE PROCTER & GAMBLE COMPANY (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6632948-B2 | Such as azethidine-2-carboxylic acid,N-carboxyamino acid anhydrides; drug intermediates | KANEKA CORPORATION (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030105072-A1 | Compounds, compositions, and methods for controlling biofilms | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2002088298-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROLLING BIOFILMS | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020151721-A1 | Novel azetidine derivative and process for preparation thereof | KANEKA CORPORATION (JP) | 2002-10-17 | — | — | US | disclosed |
| EP-1188756-A1 | NOVEL AZETIDINE DERIVATIVE AND PROCESS FOR PREPARATION THEREOF | Kaneka Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| CN-1005337-B | PREPARATION OF NOVEL PLATINUM COMPLEXES | 中外制药株式会社 | 1989-10-04 | — | — | CN | disclosed |
| US-4822892-A | ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1989-04-18 | — | — | US | disclosed |
| EP-0176005-A1 | Novel platinum complexes | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-04-02 | — | — | EP | disclosed |
| EP-0176005-A1 | Novel platinum complexes | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-04-02 | — | — | EP | disclosed |